詳細検索

詳細検索

お問い合わせ

Clinical Decision Support System Market by Type, Function, Indication, End User AI CDSS - Global Forecast to 2031

Clinical Decision Support System Market by Type, Function, Indication, End User AI CDSS - Global Forecast to 2031


The clinical decision support systems (CDSS) market is expected to grow from USD 5.80 billion in 2026 to USD 10.15 billion by 2031, reflecting a CAGR of 11.8% over the forecast period. The increasi... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年6月18日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
408
図表数
436
言語
英語

英語原文をAIを使って翻訳しています。


 

Summary

The clinical decision support systems (CDSS) market is expected to grow from USD 5.80 billion in 2026 to USD 10.15 billion by 2031, reflecting a CAGR of 11.8% over the forecast period. The increasing integration of CDSS with electronic health records (EHRs), computerized physician order entry (CPOE) platforms, and AI-enabled healthcare workflows is significantly accelerating market expansion across healthcare organizations. A growing emphasis on reducing medication errors, improving clinical efficiency, supporting evidence-based care, and enhancing patient safety is driving broader adoption of advanced CDSS platforms across hospitals and healthcare systems. Market growth is further supported by the rising implementation of artificial intelligence, predictive analytics, natural language processing (NLP), and cloud-connected healthcare technologies within clinical environments. In addition, increasing government focus on healthcare digitization, interoperability, and value-based care models is strengthening demand for interoperable and real-time clinical decision-support solutions. Expanding investments in healthcare IT modernization, connected healthcare ecosystems, and enterprise clinical intelligence platforms are expected to further support global CDSS market growth throughout the forecast period. “By end user, hospitals and health systems are expected to witness the highest growth during the forecast period.” By end user, the CDSS market is segmented into hospitals and integrated health systems, physician and specialty practices, ambulatory care centers, and other end users. Hospitals and integrated health systems represent the largest and fastest-growing end-user segment during the forecast period, driven by the increasing deployment of enterprise healthcare technologies and growing dependence on decision support systems across healthcare settings. Healthcare institutions are actively incorporating CDSS platforms into clinician workflows, medication management systems, diagnostic processes, and patient monitoring frameworks to improve treatment accuracy, reduce clinical variation, and strengthen patient safety outcomes. Rising hospital admission volumes, the increasing prevalence of complex diseases, and mounting pressure to improve operational efficiency are further supporting large-scale adoption of intelligent decision-support technologies across hospital networks. The widespread implementation of interoperable electronic health records (EHRs), cloud-enabled healthcare infrastructure, and AI-assisted clinical applications is also reinforcing the dominance of hospitals and health systems within the global CDSS landscape. In addition, healthcare providers are increasingly investing in predictive clinical intelligence, workflow automation, and real-time care coordination capabilities to support evidence-based care delivery and enterprise-wide healthcare optimization. By deployment model, the cloud-based CDSS segment is expected to witness the highest growth during the forecast period.” Based on deployment model, the CDSS market is segmented into cloud-based and on-premises CDSS. Cloud-based CDSS are projected to register the fastest growth during the forecast period. Rising adoption of scalable, interoperable, and accessible healthcare technologies is driving this demand across healthcare environments. Healthcare providers are increasingly shifting toward cloud-enabled clinical platforms to support real-time data exchange, enterprise-wide clinical coordination, AI-assisted decision-making, and seamless integration with EHRs and digital health ecosystems. The growing need for centralized data management, flexible infrastructure, lower upfront deployment costs, and faster software updates is further accelerating adoption of cloud-based CDSS solutions across hospitals, ambulatory care centers, and multi-site healthcare networks. In addition, the expanding use of telehealth, connected care solutions, remote patient monitoring systems, and AI-driven healthcare applications is strengthening demand for cloud-native decision-support technologies that enable continuous, data-driven patient care. Rising investments in healthcare cloud infrastructure are expected to further support strong segment growth throughout the forecast period. “Asia Pacific is estimated to register the highest CAGR during the forecast period.” The CDSS market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific CDSS market is projected to register the highest CAGR during the forecast period. Rapid adoption of digital healthcare infrastructure, increased implementation of health information systems based on interoperability standards, and the adoption of AI technologies are among the main drivers of this trend. Healthcare organizations in countries such as India, China, Japan, South Korea, Singapore, and Indonesia are actively promoting the modernization of clinical environments with cloud-powered health platforms, EHR systems, and AI-supported clinical solutions. Rising prevalence of chronic diseases, growing patient populations, and increasing demand for evidence-based clinical workflows are further accelerating the adoption of advanced decision-support technologies across hospitals and healthcare networks in the region. Governments are also strengthening national digital health initiatives and interoperability programs to support connected healthcare delivery and longitudinal patient data management. In May 2026, India’s Ayushman Bharat Digital Mission (ABDM) reported that more than 100 crore health records had been linked to ABHA accounts, reflecting substantial progress in interoperable healthcare infrastructure development and digital patient record integration. Increasing investments in healthcare IT modernization, scalable clinical intelligence platforms, and AI-enabled healthcare ecosystems are expected to continue driving strong CDSS market growth across Asia Pacific throughout the forecast period. In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace. • By Company Type: Tier 1 - 45%, Tier 2 - 35%, and Tier - 20% • By Designation: C-level Executives - 26%, Directors - 17%, and Others - 57% • By Region: North America – 40%, Europe – 20%, Asia Pacific – 30%, Latin America – 5%, and Middle East – 4% Wolters Kluwer (Netherlands), Epic Systems (US), Oracle Health (US), Optum (US), Merative (US), Veradigm LLC (US), and Athenahealth, Inc. (US) are key players in the CDSS market. The study includes an in-depth competitive analysis of these key players in the CDSS market, with their company profiles, recent developments, and key market strategies. Research Coverage The report analyzes the CDSS market. It estimates the market size and future growth potential across segments by component, type, technology, deployment, function, indication, end-user, and region. The report also provides a competitive analysis of key players in this market, including their company profiles, product offerings, recent developments, and key market strategies. Reasons to buy this report The report will provide market leaders and new entrants with the closest approximations of revenue figures for the CDSS market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers (increasing adoption of Al-integrated and EHR-integrated CDSS, rising incidence of medication errors and clinical inefficiencies, growing government focus on digitization, interoperability, and value-based care), restraints (data security concerns, interoperability and integration complexity), opportunities (expansion of predictive analytics and generative Al, increasing adoption of cloud-based and interoperable healthcare ecosystems, high growth potential in emerging economies), and challenges (high implementation costs of enterprise CDSS platforms, shortage of AI-skilled healthcare professionals) influencing the growth of the CDSS market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the CDSS market • Market Development: Comprehensive information about lucrative markets, the report analyzes the CDSS market across varied regions • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the CDSS market • Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players such as Wolters Kluwer (Netherlands), Epic Systems (US), Oracle Health (US), Optum (US), Merative (US), Veradigm LLC (US), Athenahealth, Inc. (US), Elsevier (Netherlands), Zynx Health (US), Koninklijke Philips N.V. (Netherlands), and Medical Information Technology, Inc. (MEDITECH) (US), among others in the CDSS market.

ページTOPに戻る


Table of Contents

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 MARKET SCOPE 35
1.3.1 MARKETS COVERED 35
1.3.2 INCLUSIONS AND EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 37
1.4 CURRENCY CONSIDERED 37
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 38
2 EXECUTIVE SUMMARY 39
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 39
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 41
2.3 DISRUPTIVE TRENDS SHAPING MARKET 42
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 43
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 44
3 PREMIUM INSIGHTS 45
3.1 CLINICAL DECISION SUPPORT SYSTEM MARKET OVERVIEW 45
3.2 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT AND COUNTRY 46
3.3 CLINICAL DECISION SUPPORT SYSTEMS MARKET: REGIONAL GROWTH OPPORTUNITIES 46
4 MARKET OVERVIEW 47
4.1 INTRODUCTION 47
4.2 MARKET DYNAMICS 48
4.2.1 DRIVERS 48
4.2.1.1 Growing government focus on digitization, interoperability, and value-based care 48
4.2.1.2 Increasing adoption of Al-integrated and EHR-integrated CDSS 50
4.2.1.3 Rising incidence of medication errors and clinical inefficiencies 50
4.2.2 RESTRAINTS 51
4.2.2.1 Data security concerns 51
4.2.2.2 Interoperability and integration complexity 51
4.2.3 OPPORTUNITIES 52
4.2.3.1 Expansion of predictive analytics and Generative Al 52
4.2.3.2 High growth potential in emerging economies 52
4.2.3.3 Increasing adoption of cloud-based and interoperable
healthcare ecosystems 53
4.2.4 CHALLENGES 54
4.2.4.1 High implementation costs of enterprise CDSS platforms 54
4.2.4.2 Shortage of Al-skilled healthcare professionals 54
4.3 UNMET NEEDS AND WHITE SPACES 55
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 55
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 56
5 INDUSTRY TRENDS 57
5.1 PORTER'S FIVE FORCES ANALYSIS 57
5.1.1 THREAT OF NEW ENTRANTS 58
5.1.2 THREAT OF SUBSTITUTES 58
5.1.3 BARGAINING POWER OF SUPPLIERS 58
5.1.4 BARGAINING POWER OF BUYERS 58
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.2 MACROECONOMIC INDICATORS 59
5.2.1 INTRODUCTION 59
5.2.2 GDP TRENDS AND FORECAST 59
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 59
5.3 VALUE CHAIN ANALYSIS 60
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 61
5.3.2 DATA & KNOWLEDGE ASSETS 61
5.3.3 SOFTWARE & PLATFORM INFRASTRUCTURE 62
5.3.4 CLOUD SERVICE PROVIDERS 62
5.3.5 MARKETING & SALES 62
5.3.6 POST-SALES SERVICES 62
5.4 ECOSYSTEM ANALYSIS 62
5.5 PRICING ANALYSIS 65
5.5.1 INDICATIVE PRICE FOR CDSS MARKET, BY PRODUCT (2025) 66
5.5.2 INDICATIVE PRICE FOR CDSS MAREKT, BY REGION (2025) 67
5.6 KEY CONFERENCES AND EVENTS 67
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
5.8 INVESTMENTS AND FUNDING 69
5.9 CASE STUDY ANALYSIS 70
5.9.1 IMPROVING PATIENT OUTCOMES 70
5.9.2 IMPROVING CLINICAL DECISION-MAKING 71
5.9.3 ENHANCING MEDICATION SAFETY 71
5.9.4 INCREASING CLINICAL EFFICIENCY 72
5.10 IMPACT OF 2025 US TARIFF—OVERVIEW 72
5.10.1 INTRODUCTION 72
5.10.2 KEY TARIFF RATES 73
5.10.3 PRICE IMPACT ANALYSIS 73
5.10.4 IMPACT ON COUNTRY/REGION 74
5.10.4.1 The US 74
5.10.4.2 Europe 74
5.10.4.3 APAC 74
5.10.5 IMPACT ON END USE INDUSTRIES 75
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTION 77
6.1 KEY EMERGING TECHNOLOGIES 77
6.1.1 DEEP LEARNING & PREDICTIVE CLINICAL ANALYTICS TECHNOLOGIES 77
6.1.2 NATURAL LANGUAGE PROCESSING (NLP) & GENERATIVE AI TECHNOLOGIES 77
6.1.3 REAL-TIME INTELLIGENCE & WORKFLOW-ORIENTED AI TECHNOLOGIES 78
6.2 COMPLEMENTARY TECHNOLOGIES 78
6.2.1 ELECTRONIC HEALTH RECORDS (EHR), FHIR & HEALTHCARE INTEROPERABILITY TECHNOLOGIES 78
6.2.2 CLOUD-BASED, EDGE & HYBRID CLINICAL COMPUTING TECHNOLOGIES 79
6.3 ADJACENT TECHNOLOGIES 79
6.3.1 AMBIENT CLINICAL OPERATIONAL & DOCUMENTATION TECHNOLOGIES 79
6.3.2 DIAGNOSTIC AND IMAGING TECHNOLOGIES 79
6.4 TECHNOLOGY/PRODUCT ROADMAP 80
6.5 PATENT ANALYSIS 81
6.5.1 PATENT PUBLICATION TRENDS FOR CLINICAL DECISION SUPPORT SYSTEMS 81
6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 82
6.5.3 LIST OF SOME PATENTS/PATENT APPLICATIONS FOR CDSS 85
6.6 FUTURE APPLICATIONS 86
6.6.1 AI-ASSISTED PERSONALIZED CLINICAL DECISION SUPPORT 87
6.6.2 AMBIENT CLINICAL INTELLIGENCE & AUTONOMOUS WORKFLOW ASSISTANCE 87
6.6.3 PREDICTIVE POPULATION HEALTH & CONTINUOUS CARE MANAGEMENT 87
6.7 IMPACT OF AI/GEN AI ON CDSS MARKET 88
6.7.1 INTRODUCTION 88
6.7.2 MARKET POTENTIAL OF AI/GEN AI IN CDSS MARKET 89
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 90
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 91
6.7.4.1 Electronic Health Records (EHR) & Healthcare Interoperability 91
6.7.4.2 Remote Patient Monitoring (RPM), Telehealth & Digital Care 91
6.7.4.3 Population Health Management (PHM) 92
6.7.5 USER READINESS AND IMPACT ASSESSMENT 92
6.7.5.1 User Readiness 92
6.7.5.1.1 User A: Hospitals & Integrated Health Systems 92
6.7.5.1.2 User B: Ambulatory Care Centers & Physician Practices 92
6.7.5.2 Impact Assessment 93
6.7.5.2.1 User A: Hospitals & Integrated Health Systems 93
6.7.5.2.1.1 IMPLEMENTATION 93
6.7.5.2.1.2 IMPACT 93
6.7.5.2.2 User B: Ambulatory Care Centers & Physician Practices 93
6.7.5.2.2.1 IMPLEMENTATION 93
6.7.5.2.2.1.1 IMPACT 94
7 REGULATORY LANDSCAPE 95
7.1 REGIONAL REGULATIONS AND COMPLIANCE 95
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
7.1.2 REGULATORY FRAMEWORK 101
7.1.2.1 North America 101
7.1.2.2 Europe 102
7.1.2.3 Asia Pacific 102
7.1.2.4 Latin America 103
7.1.2.5 Middle East & Africa 104
7.1.3 INDUSTRY STANDARDS 104
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 106
8.1 INTRODUCTION 106
8.2 DECISION-MAKING PROCESS 106
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 106
8.4 KEY STAKEHOLDERS IN BUYING PROCESS 107
8.4.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
8.4.2 BUYING CRITERIA 108
8.5 ADOPTION BARRIERS & INTERNAL CHALLENGES 109
8.6 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109
8.6.1 UNMET NEEDS 110
8.6.2 END-USER EXPECTATIONS 111
8.7 MARKET PROFITABILITY 113
9 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT 114
9.1 INTRODUCTION 115
9.2 SOFTWARE 115
9.2.1 INTEGRATED CDSS 116
9.2.1.1 EHR integration and real-time clinical decision support to drive market growth 116
9.2.2 STANDALONE CDSS 117
9.2.2.1 Specialized clinical decision support applications to support market growth 117
9.3 SERVICES 118
9.3.1 SPECIALIZED APPLICATIONS TO SUPPORT RECURRING REQUIREMENT TO DRIVE MARKET 118
10 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE 120
10.1 INTRODUCTION 121
10.2 THERAPEUTIC CDSS 121
10.2.1 INCREASING DEMAND FOR EVIDENCE-BASED TREATMENT DECISION SUPPORT TO DRIVE MARKET GROWTH 121
10.3 DIAGNOSTIC CDSS 122
10.3.1 INCREASING DEMAND FOR ACCURATE AND TIMELY DIAGNOSTIC DECISION SUPPORT TO BOOST MARKET 122
11 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY 124
11.1 INTRODUCTION 125
11.2 KNOWLEDGE-BASED CDSS 125
11.2.1 DEPLOYS CONDITIONAL LOGIC FOR DECISION-MAKING AND PROBLEM ANALYSIS 125
11.3 NON-KNOWLEDGE-BASED CDSS 127
11.3.1 ADVANCEMENTS IN AI AND PREDICTIVE ANALYTICS TO DRIVE MARKET EXPANSION 127
12 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL 129
12.1 INTRODUCTION 130
12.2 CLOUD-BASED 130
12.2.1 SCALABILITY, INTEROPERABILITY, AND AI-ENABLED WORKFLOWS BOOST GROWTH 130
12.3 ON-PREMISES 131
12.3.1 GREATER DATA CONTROL AND CUSTOMIZATION TO SUPPORT CONTINUED ADOPTION 131
13 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION 133
13.1 INTRODUCTION 134
13.2 MEDICATION MANAGEMENT SUPPORT 134
13.2.1 INCREASING FOCUS ON MEDICATION SAFETY AND ERROR REDUCTION TO DRIVE MARKET GROWTH 134
13.3 DIAGNOSTIC DECISION SUPPORT 135
13.3.1 GROWING DEMAND FOR ACCURATE AND TIMELY DIAGNOSTIC INSIGHTS TO DRIVE MARKET GROWTH 135
13.4 TREATMENT PLANNING & CLINICAL PATHWAY SUPPORT 136
13.4.1 INCREASING ADOPTION OF EVIDENCE-BASED CARE PATHWAYS TO SUPPORT MARKET EXPANSION 136
13.5 RISK PREDICTION & PREVENTIVE CARE 137
13.5.1 EXPANDING USE OF PREDICTIVE ANALYTICS TO DRIVE MARKET GROWTH 137
13.6 OTHER FUNCTIONS 138
14 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION 139
14.1 INTRODUCTION 140
14.2 PRIMARY CARE & GENERAL MEDICINE 140
14.2.1 INCREASING DEMAND FOR EVIDENCE-BASED DECISION SUPPORT IN HIGH-VOLUME CARE SETTINGS TO DRIVE MARKET GROWTH 140
14.3 ONCOLOGY 141
14.3.1 INCREASING COMPLEXITY OF CANCER CARE SUPPORTS MARKET EXPANSION 141
14.4 CARDIOLOGY 142
14.4.1 GROWING DEMAND FOR CARDIOVASCULAR RISK STRATIFICATION AND CLINICAL DECISION SUPPORT 142
14.5 CRITICAL CARE & EMERGENCY MEDICINE 143
14.5.1 REAL-TIME CLINICAL DECISION SUPPORT TO IMPROVE ACUTE CARE OUTCOMES 143
14.6 NEUROLOGY 144
14.6.1 ADVANCEMENTS IN AI-ENABLED NEUROLOGICAL DECISION SUPPORT TO DRIVE MARKET GROWTH 144
14.7 OTHERS 145
14.7.1 ABILITY TO ENABLE OPTIMAL DECISION-MAKING WITH MINIMAL ERRORS TO DRIVE MARKET 145
15 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER 146
15.1 INTRODUCTION 147
15.2 HOSPITALS & HEALTH SYSTEMS 147
15.2.1 INCREASING ADOPTION OF ENTERPRISE-WIDE CLINICAL DECISION SUPPORT TO DRIVE MARKET GROWTH 147
15.3 PHYSICIAN & SPECIALTY PRACTICES 148
15.3.1 GROWING NEED FOR EFFICIENT CLINICAL DECISION-MAKING TO SUPPORT MARKET EXPANSION 148
15.4 AMBULATORY CARE CENTERS 149
15.4.1 EXPANDING OUTPATIENT CARE DELIVERY TO ACCELERATE CDSS ADOPTION 149
15.5 OTHER END USERS 150
15.5.1 EXPANDING UTILIZATION OF CLINICAL DECISION SUPPORT ACROSS DIVERSE HEALTHCARE SETTINGS 150
16 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION 151
16.1 INTRODUCTION 152
16.2 NORTH AMERICA 152
16.2.1 NORTH AMERICA: MACROECONOMIC IMPACT 152
16.2.2 US 157
16.2.2.1 Expansion of AI-enabled value-based care to accelerate CDSS adoption 157
16.2.3 CANADA 161
16.2.3.1 Accelerating digital health interoperability to strengthen CDSS adoption 161
16.3 EUROPE 164
16.3.1 EUROPE: MACROECONOMIC IMPACT 165
16.3.2 GERMANY 168
16.3.2.1 Favorable government support for digital health and electronic patient records to propel market 168
16.3.3 UK 172
16.3.3.1 NHS digital transformation and interoperable healthcare infrastructure drive market 172
16.3.4 FRANCE 175
16.3.4.1 Robust interoperability for EHR systems to drive market 175
16.3.5 ITALY 179
16.3.5.1 Expansion of interoperable electronic health records to accelerate CDSS adoption 179
16.3.6 SPAIN 182
16.3.6.1 Growing adoption of interoperable electronic health records to support market growth 182
16.3.7 REST OF EUROPE 185
16.4 ASIA PACIFIC 188
16.4.1 ASIA PACIFIC: MACROECONOMIC IMPACT 189
16.4.2 JAPAN 193
16.4.2.1 Medical DX initiatives and standardized electronic medical records to propel market 193
16.4.3 CHINA 196
16.4.3.1 Government-led digital hospital transformation and EMR maturity to drive market 196
16.4.4 INDIA 199
16.4.4.1 Expansion of Ayushman Bharat Digital Mission to accelerate CDSS adoption 199
16.4.5 AUSTRALIA 203
16.4.5.1 Nationwide adoption of My Health Record to accelerate CDSS deployment 203
16.4.6 SOUTH KOREA 206
16.4.6.1 Government-led digital health regulations and AI adoption to drive market 206
16.4.7 REST OF ASIA PACIFIC 210
16.5 LATIN AMERICA 213
16.5.1 LATIN AMERICA: MACROECONOMIC IMPACT 214
16.5.2 BRAZIL 217
16.5.2.1 Strengthening national health information exchange to accelerate CDSS adoption 217
16.5.3 MEXICO 220
16.5.3.1 Digital transformation initiatives in healthcare to support CDSS adoption 220
16.5.4 REST OF LATIN AMERICA 223
16.5.4.1 Growing healthcare digitalization to support CDSS adoption 223
16.6 MIDDLE EAST & AFRICA 226
16.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC IMPACT 227
16.6.2 GCC COUNTRIES 230
16.6.2.1 Rising demand to digitize healthcare IT to propel market 230
16.6.3 SAUDI ARABIA 234
16.6.3.1 National digital health transformation to accelerate CDSS adoption 234
16.6.4 UAE 237
16.6.4.1 Expansion of nationwide health information exchange to drive market 237
16.6.5 OTHER GCC COUNTRIES 240
16.6.5.1 Increasing digital health investments to support CDSS adoption 240
16.6.6 SOUTH AFRICA 243
16.6.6.1 Focus on modernizing healthcare systems to drive market 243
16.6.7 REST OF MIDDLE EAST & AFRICA 246
16.6.7.1 Growing government-led digital health initiatives to support market growth 246
17 COMPETITIVE LANDSCAPE 250
17.1 OVERVIEW 250
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 250
17.3 REVENUE ANALYSIS, 2021-2025 253
17.4 MARKET SHARE ANALYSIS, 2021–2025 254
17.5 BRAND COMPARISON 257
17.6 COMPANY VALUATION AND FINANCIAL METRICS 258
17.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 259
17.7.1 STARS 259
17.7.2 EMERGING LEADERS 259
17.7.3 PERVASIVE PLAYERS 259
17.7.4 PARTICIPANTS 259
17.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 261
17.7.5.1 Company footprint 261
17.7.5.2 Region footprint 262
17.7.5.3 Component footprint 263
17.7.5.4 Type footprint 264
17.7.5.5 Technology footprint 265
17.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 266
17.8.1 PROGRESSIVE COMPANIES 266
17.8.2 RESPONSIVE COMPANIES 266
17.8.3 DYNAMIC COMPANIES 266
17.8.4 STARTING BLOCKS 266
17.8.4.1 COMPETITIVE BENCHMARKING STARTUPS/SMES, 2025 267
17.9 COMPETITIVE SCENARIO 269
17.9.1 DEALS 271
17.9.2 OTHER DEVELOPMENTS 275
18 COMPANY PROFILES 277
18.1 KEY PLAYERS 277
18.1.1 WOLTERS KLUWER N.V. 277
18.1.1.1 Business overview 277
18.1.1.2 Product/solutions/services s offered 279
18.1.1.3 Recent developments 280
18.1.1.3.1 Product launches & upgrades 280
18.1.1.3.2 Deals 281
18.1.1.3.3 Other developments 284
18.1.1.4 MnM view 284
18.1.1.4.1 Key strengths 284
18.1.1.4.2 Strategic choices 285
18.1.1.4.3 Weaknesses and competitive threats 285
18.1.2 EPIC SYSTEMS CORPORATION 286
18.1.2.1 Business overview 286
18.1.2.2 Products/solutions/services offered 287
18.1.2.3 Recent developments 289
18.1.2.3.1 Product launches & upgrades 289
18.1.2.3.2 Deals 290
18.1.2.3.3 Other developments 291
18.1.2.4 MnM view 291
18.1.2.4.1 Key strengths 291
18.1.2.4.2 Strategic choices 292
18.1.2.4.3 Weaknesses and competitive threats 292
18.1.3 ORACLE 293
18.1.3.1 Business overview 293
18.1.3.2 Products/solutions/services offered 294
18.1.3.3 Recent developments 296
18.1.3.3.1 Product launches & upgrades 296
18.1.3.3.2 Deals 297
18.1.3.4 MnM view 299
18.1.3.4.1 Key strengths 299
18.1.3.4.2 Strategic choices 299
18.1.3.4.3 Weaknesses and competitive threats 299
18.1.4 MERATIVE 300
18.1.4.1 Business overview 300
18.1.4.2 Products/solutions/services offered 300
18.1.4.3 Recent developments 301
18.1.4.3.1 Product launches & upgrades 301
18.1.4.3.2 Deals 301
18.1.4.3.3 Other developments 302
18.1.4.4 MnM view 302
18.1.4.4.1 Key strengths 302
18.1.4.4.2 Strategic choices 303
18.1.4.4.3 Weaknesses and competitive threats 303
18.1.5 VERADIGM LLC 304
18.1.5.1 Business overview 304
18.1.5.2 Products/solutions/services offered 305
18.1.5.3 Recent developments 307
18.1.5.3.1 Product launches & upgrades 307
18.1.5.3.2 Deals 308
18.1.5.3.3 Other developments 309
18.1.5.4 MnM view 309
18.1.5.4.1 Key strengths 309
18.1.5.4.2 Strategic choices 310
18.1.5.4.3 Weaknesses and competitive threats 310
18.1.6 OPTUM, INC. (UNITEDHEALTH GROUP) 311
18.1.6.1 Business overview 311
18.1.6.2 Products/solutions/services offered 312
18.1.6.3 Recent developments 313
18.1.6.3.1 Product launches & upgrades 313
18.1.6.3.2 Deals 314
18.1.7 ATHENAHEALTH 315
18.1.7.1 Business overview 315
18.1.7.2 Products/solutions/services offered 316
18.1.7.3 Recent developments 316
18.1.7.3.1 Product launches & upgrades 316
18.1.7.3.2 Deals 317
18.1.8 ELSEVIER (DIVISION OF RELX GROUP) 319
18.1.8.1 Business overview 319
18.1.8.2 Products/solutions/services offered 320
18.1.8.3 Recent developments 322
18.1.8.3.1 Product launches & upgrades 322
18.1.8.3.2 Deals 323
18.1.9 ZYNX HEALTH, INC. 324
18.1.9.1 Business overview 324
18.1.9.2 Products/solutions/services offered 325
18.1.9.3 Recent developments 326
18.1.9.3.1 Product launches & upgrades 326
18.1.9.3.2 Deals 326
18.1.9.3.3 Other developments 326
18.1.10 KONINKLIJKE PHILIPS N.V. 327
18.1.10.1 Business overview 327
18.1.10.2 Products/solutions/services offered 328
18.1.10.3 Recent developments 330
18.1.10.3.1 Product launches & upgrades 330
18.1.10.3.2 Deals 331
18.1.11 MEDICAL INFORMATION TECHNOLOGY, INC. 333
18.1.11.1 Business overview 333
18.1.11.2 Products/solutions/services offered 334
18.1.11.3 Recent developments 335
18.1.11.3.1 Product launches & upgrades 335
18.1.11.3.2 Deals 336
18.1.11.3.3 Other developments 337
18.1.12 NEXTGEN HEALTHCARE, INC. 338
18.1.12.1 Business overview 338
18.1.12.2 Products/solutions/services offered 340
18.1.12.3 Recent developments 341
18.1.12.3.1 Product launches & upgrades 341
18.1.12.3.2 Deals 342
18.1.13 CUREMD HEALTHCARE 345
18.1.13.1 Business overview 345
18.1.13.2 Products/solutions/services offered 346
18.1.13.3 Recent developments 347
18.1.13.3.1 Product Launches & upgrades 347
18.1.13.3.2 Deals 348
18.1.13.3.3 Other developments 348
18.1.14 SIEMENS HEALTHINEERS AG 349
18.1.14.1 Business overview 349
18.1.14.2 Products/solutions/services offered 350
18.1.14.3 Recent developments 352
18.1.14.3.1 Products launches & upgrades 352
18.1.14.3.2 Deals 352
18.1.15 EBSCO INFORMATION SERVICES 354
18.1.15.1 Business overview 354
18.1.15.2 Products/solutions/services offered 355
18.1.15.3 Recent developments 356
18.1.15.3.1 Product launches & upgrades 356
18.1.15.3.2 Deals 357
18.1.16 GE HEALTHCARE 358
18.1.16.1 Business overview 358
18.1.16.2 Products/solutions/services offered 360
18.1.16.3 Recent developments 361
18.1.16.3.1 Product launches & upgrades 361
18.1.16.3.2 Deals 362
18.1.16.3.3 Other developments 365
18.1.17 ECLINICALWORKS, LLC 366
18.1.17.1 Business overview 366
18.1.17.2 Products/Solutions/Services Offered 367
18.1.17.3 Recent developments 367
18.1.17.3.1 Product launches & upgrades 367
18.1.17.4 Recent developments 368
18.1.17.4.1 Deals 368
18.1.18 THE MEDICAL ALGORITHMS COMPANY LIMITED 370
18.1.18.1 Business overview 370
18.1.18.2 Products/solutions/services offered 371
18.1.19 CARECLOUD, INC. 372
18.1.19.1 Business overview 372
18.1.19.2 Products/solutions/services offered 373
18.1.19.3 Recent developments 374
18.1.19.3.1 Product launches & upgrades 374
18.1.19.3.2 Deals 375
18.1.20 VISUALDX 377
18.1.20.1 Business overview 377
18.1.20.2 Products/solutions/services offered 378
18.1.20.3 Recent developments 379
18.1.20.3.1 Deals 379
18.2 OTHER PLAYERS 380
18.2.1 MACUSOFT 380
18.2.2 HERA-MI 380
18.2.3 COHESIC INC. 381
18.2.4 MEDEA MIND 381
18.2.5 GLASS HEALTH 382
18.2.6 MEDECIPHER 382
19 RESEARCH METHODOLOGY 383
19.1 RESEARCH APPROACH 383
19.1.1 SECONDARY RESEARCH 384
19.1.1.1 Key data from secondary sources 385
19.1.2 PRIMARY RESEARCH 385
19.1.2.1 Key data from primary sources 387
19.1.2.2 Insights from primary experts 388
19.2 RESEARCH METHODOLOGY 389
19.3 MARKET SIZE ESTIMATION 391
19.4 MARKET BREAKDOWN DATA TRIANGULATION 396
19.5 MARKET SHARE ESTIMATION 397
19.6 STUDY ASSUMPTIONS 397
19.7 LIMITATIONS 398
19.7.1 SCOPE-RELATED LIMITATIONS 398
19.7.2 METHODOLOGY-RELATED LIMITATIONS 398
19.8 RISK ASSESSMENT 398
20 APPENDIX 399
20.1 DISCUSSION GUIDE 399
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 404
20.3 CUSTOMIZATION OPTIONS 406
20.4 RELATED REPORTS 406
20.5 AUTHOR DETAILS 407

ページTOPに戻る



List of Tables/Graphs

TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD 37
TABLE 2 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PORTER’S FIVE FORCES ANALYSIS 58
TABLE 3 CDSS MARKET: ROLE IN ECOSYSTEM 65
TABLE 4 INDICATIVE PRICE FOR CDSS MAREKT, BY REGION (2025) 67
TABLE 5 CLINICAL DECISION SUPPORT SYSTEMS: DETAILED LIST OF CONFERENCES
AND EVENTS (2026–2027) 67
TABLE 6 CASE 1: RISING FOCUS ON IMPROVING PATIENT SAFETY 70
TABLE 7 CASE 2: IMPROVING CLINICAL DECISION-MAKING THROUGH PROVINCE-WIDE HEALTH INFORMATION TRANSFORMATION 71
TABLE 8 CASE 3: ENHANCING MEDICATION SAFETY THROUGH PERSONALIZED
DECISION SUPPORT 71
TABLE 9 CASE 4: IMPROVING CLINICAL EFFICIENCY THROUGH ENTERPRISE EHR MODERNIZATION 72
TABLE 10 US ADJUSTED RECIPROCAL TARIFF RATES 73
TABLE 11 TOP APPLICANT COUNTRIES FOR CDSS PATENTS 83
TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 13 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 97
TABLE 14 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 98
TABLE 15 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 99
TABLE 16 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
TABLE 17 REGULATORY SCENARIO OF NORTH AMERICA 101
TABLE 18 REGULATORY SCENARIO OF EUROPE 102
TABLE 19 REGULATORY SCENARIO OF ASIA PACIFIC 102
TABLE 20 REGULATORY SCENARIO OF LATIN AMERICA 103
TABLE 21 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 104
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 108
TABLE 23 BUYING CRITERIA FOR COMPONENTS, BY RANK 109
TABLE 24 UNMET NEEDS IN CDSS MARKET 110
TABLE 25 END-USER EXPECTATIONS IN CDSS MARKET 112
TABLE 26 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 115
TABLE 27 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SOFTWARE,
BY REGION, 2024–2031 (USD MILLION) 115
TABLE 28 INTEGRATED CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 117
TABLE 29 STANDALONE CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 118
TABLE 30 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SERVICES,
BY REGION, 2024–2031 (USD MILLION) 119
TABLE 31 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 121
TABLE 32 THERAPEUTIC CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 122
TABLE 33 DIAGNOSTIC CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 123
TABLE 34 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 125
TABLE 35 KNOWLEDGE-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 126
TABLE 36 NON-KNOWLEDGE-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 128
TABLE 37 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 130
TABLE 38 CLOUD-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 39 ON-PREMISE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 40 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 134
TABLE 41 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR MEDICATION MANAGEMENT SUPPORT, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 42 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR DIAGNOSTIC DECISION SUPPORT, BY REGION, 2024–2031 (USD MILLION) 136
TABLE 43 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR TREATMENT PLANNING & CLINICAL PATHWAY SUPPORT, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 44 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR RISK PREDICTION & PREVENTIVE CARE, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 45 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR OTHER FUNCTIONS,
BY REGION, 2024–2031 (USD MILLION) 138
TABLE 46 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 140
TABLE 47 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR PRIMARY CARE & GENERAL MEDICINE, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 48 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 49 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR CARDIOLOGY, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 50 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR CRITICAL CARE & EMERGENCY MEDICINE, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 51 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 144
TABLE 52 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR OTHER INDICATIONS,
BY REGION, 2024–2031 (USD MILLION) 145
TABLE 53 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 147
TABLE 54 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR HOSPITALS & HEALTH SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 148
TABLE 55 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR PHYSICIAN & SPECIALTY PRACTICES, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 56 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2024–2031 (USD MILLION) 150
TABLE 57 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 150
TABLE 58 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 152
TABLE 59 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 60 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 154
TABLE 61 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 154
TABLE 62 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 155
TABLE 63 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 155
TABLE 64 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 155
TABLE 65 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 156
TABLE 66 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 156
TABLE 67 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 157
TABLE 68 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 158
TABLE 69 US: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE,
2024–2031 (USD MILLION) 158
TABLE 70 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 159
TABLE 71 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 159
TABLE 72 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 159
TABLE 73 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 160
TABLE 74 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 160
TABLE 75 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 161
TABLE 76 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 162
TABLE 77 CANADA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 162
TABLE 78 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 162
TABLE 79 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 163
TABLE 80 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 163
TABLE 81 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 163
TABLE 82 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 164
TABLE 83 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 164
TABLE 84 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 85 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 166
TABLE 86 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 166
TABLE 87 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 166
TABLE 88 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 167
TABLE 89 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 167
TABLE 90 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 167
TABLE 91 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 168
TABLE 92 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 168
TABLE 93 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 169
TABLE 94 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 169
TABLE 95 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 170
TABLE 96 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 170
TABLE 97 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 170
TABLE 98 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 171
TABLE 99 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 171
TABLE 100 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 172
TABLE 101 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 173
TABLE 102 UK: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 103 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 173
TABLE 104 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 174
TABLE 105 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 174
TABLE 106 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 174
TABLE 107 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 175
TABLE 108 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 175
TABLE 109 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 176
TABLE 110 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 176
TABLE 111 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 177
TABLE 112 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 177
TABLE 113 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 177
TABLE 114 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 178
TABLE 115 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 178
TABLE 116 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 179
TABLE 117 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 180
TABLE 118 ITALY: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 180
TABLE 119 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 180
TABLE 120 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 181
TABLE 121 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 181
TABLE 122 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 181
TABLE 123 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 182
TABLE 124 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 182
TABLE 125 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 183
TABLE 126 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 127 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 183
TABLE 128 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 184
TABLE 129 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 184
TABLE 130 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 184
TABLE 131 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 185
TABLE 132 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 185
TABLE 133 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 186
TABLE 134 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 135 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 136 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 187
TABLE 137 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 187
TABLE 138 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 187
TABLE 139 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 188
TABLE 140 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 188
TABLE 141 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 142 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 191
TABLE 143 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 144 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 191
TABLE 145 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 192
TABLE 146 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 192
TABLE 147 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION LEVEL, 2024–2031 (USD MILLION) 192
TABLE 148 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 193
TABLE 149 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 193
TABLE 150 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 194
TABLE 151 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 152 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 194
TABLE 153 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 195
TABLE 154 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 195
TABLE 155 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 195
TABLE 156 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 196
TABLE 157 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 196
TABLE 158 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 197
TABLE 159 CHINA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 160 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 197
TABLE 161 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 198
TABLE 162 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 198
TABLE 163 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 198
TABLE 164 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 199
TABLE 165 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 199
TABLE 166 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 200
TABLE 167 INDIA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 168 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 201
TABLE 169 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 201
TABLE 170 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 201
TABLE 171 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 202
TABLE 172 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 202
TABLE 173 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 203
TABLE 174 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 204
TABLE 175 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 176 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 204
TABLE 177 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 205
TABLE 178 AUSTRALIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 205
TABLE 179 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 205
TABLE 180 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 206
TABLE 181 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 206
TABLE 182 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 207
TABLE 183 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 184 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 208
TABLE 185 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 208
TABLE 186 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 208
TABLE 187 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 209
TABLE 188 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 209
TABLE 189 SOUTH KOREA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 210
TABLE 190 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 211
TABLE 191 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 192 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 193 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 212
TABLE 194 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 212
TABLE 195 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY FUNCTION, 2024–2031 (USD MILLION) 212
TABLE 196 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 213
TABLE 197 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 213
TABLE 198 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 199 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 214
TABLE 200 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 201 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 202 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 215
TABLE 203 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 216
TABLE 204 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 216
TABLE 205 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 217
TABLE 206 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 217
TABLE 207 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 218
TABLE 208 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 209 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 210 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 219
TABLE 211 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 219
TABLE 212 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 219
TABLE 213 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 220
TABLE 214 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 215 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 221
TABLE 216 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 217 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 221
TABLE 218 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222
TABLE 219 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 222
TABLE 220 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 222
TABLE 221 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 223
TABLE 222 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 223
TABLE 223 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 224
TABLE 224 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 225 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 226 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 225
TABLE 227 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 225
TABLE 228 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY FUNCTION, 2024–2031 (USD MILLION) 225
TABLE 229 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 226
TABLE 230 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 226
TABLE 231 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 232 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 227
TABLE 233 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 234 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 235 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 228
TABLE 236 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 229
TABLE 237 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY FUNCTION, 2024–2031 (USD MILLION) 229
TABLE 238 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 230
TABLE 239 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 230
TABLE 240 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 241 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 231
TABLE 242 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 243 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 244 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 232
TABLE 245 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 232
TABLE 246 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY FUNCTION, 2024–2031 (USD MILLION) 233
TABLE 247 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 233
TABLE 248 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 234
TABLE 249 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 234
TABLE 250 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 251 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 235
TABLE 252 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 235
TABLE 253 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 236
TABLE 254 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 236
TABLE 255 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 237
TABLE 256 SAUDI ARABIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 237
TABLE 257 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2024–2031 (USD MILLION) 238
TABLE 258 UAE: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 259 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 238
TABLE 260 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 239
TABLE 261 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 239
TABLE 262 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 239
TABLE 263 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 240
TABLE 264 UAE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER,
2024–2031 (USD MILLION) 240
TABLE 265 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2024–2031 (USD MILLION) 241
TABLE 266 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 267 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 268 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 242
TABLE 269 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 242
TABLE 270 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY FUNCTION, 2024–2031 (USD MILLION) 242
TABLE 271 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 243
TABLE 272 OTHER GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY END USER, 2024–2031 (USD MILLION) 243
TABLE 273 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 244
TABLE 274 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET,
BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 275 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 244
TABLE 276 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 245
TABLE 277 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 245
TABLE 278 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 245
TABLE 279 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 246
TABLE 280 SOUTH AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 246
TABLE 281 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 247
TABLE 282 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS SOFTWARE MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 283 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 284 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 248
TABLE 285 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL, 2024–2031 (USD MILLION) 248
TABLE 286 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 248
TABLE 287 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 249
TABLE 288 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER, 2024–2031 (USD MILLION) 249
TABLE 289 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CDSS MARKET,
JANUARY 2023– JUNE 2026 251
TABLE 290 CLINICAL DECISION SUPPORT SYSTEM MARKET: DEGREE OF COMPETITION 255
TABLE 291 CDSS MARKET: REGION FOOTPRINT OF KEY PLAYERS 262
TABLE 292 CDSS MARKET: COMPONENT FOOTPRINT 263
TABLE 293 CLINICAL DECISION SUPPORT SYSTEMS MARKET: TYPE FOOTPRINT 264
TABLE 294 CLINICAL DECISION SUPPORT SYSTEMS MARKET: TECHNOLOGY FOOTPRINT 265
TABLE 295 CDSS MARKET: LIST OF STARTUPS/SMES 267
TABLE 296 CDSS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 268
TABLE 297 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PRODUCT LAUNCHES AND UPGRADES (JANUARY 2023–JUNE 2026) 269
TABLE 298 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DEALS
(JANUARY 2023–JUNE 2026) 271
TABLE 299 CLINICAL DECISION SUPPORT SYSTEMS MARKET: OTHER DEVELOPMENTS (JANUARY 2023–JUNE 2026) 275
TABLE 300 WOLTERS KLUWER N.V.: BUSINESS OVERVIEW 277
TABLE 301 WOLTERS KLUWER N.V.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 279
TABLE 302 WOLTERS KLUWER N.V.: PRODUCT LAUNCHES & UPGRADES,
JANUARY 2023–JUNE 2026 280
TABLE 303 WOLTERS KLUWER N.V.: DEALS, JANUARY 2023–MAY 2026 281
TABLE 304 WOLTERS KLUWER N.V.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 284
TABLE 305 EPIC SYSTEMS CORPORATION: BUSINESS OVERVIEW 286
TABLE 306 EPIC SYSTEMS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 287
TABLE 307 EPIC SYSTEMS CORPORATION: PRODUCT LAUNCHES & UPGRADES, JANUARY 2023– JUNE 2026 289
TABLE 308 EPIC SYSTEMS CORPORATION: DEALS, JANUARY 2023–JUNE 2026 290

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

MarketsandMarkets社の Healthcare IT分野 での最新刊レポート

本レポートと同じKEY WORD(end user)の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/07/22 10:26

164.21 円

187.61 円

222.46 円

ページTOPに戻る